Global Guided Bone Regeneration Market

Guided Bone Regeneration Comprehensive Study by Type (Ceramic-based, Polymer-based, Growth factor-based, Cell-based, Others), Application (Orthopedic Surgery, Bone Trauma, Dental Surgery, Others), End Use (Hospital, Dental Clinic, Academic & Research Centers), Membrane (Reabsorbable Membranes, Non-Reabsorbable Membranes) Players and Region - Global Market Outlook to 2030

Guided Bone Regeneration Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 4.7%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Guided Bone RegenerationMarket?
GBR and GTR are dental surgical redress that use barrier membranes to direct the introduction of new bone and gingival tissue in areas the place there are inadequate portions or dimensions of bone or gingiva for perfect function, aesthetics, or prosthetic restoration. Reconstructive surgical treatment faces a hurdle with bone-regeneration techniques, whether or not the usage of autografts or allografts. Biomaterials serve as transient matrices for bone formation and tissue development, offering a unique surroundings and architecture. Certain cloth classes might also be extra or much less nicely matched to the ultimate building relying on the particular supposed software of the matrix, whether or not for structural support, drug transport capabilities, or both.

Guided Bone Regeneration Market Report Coverage
Report CoverageDetails
Study Timeframe2018 to 2030
Base Year2023
Forecast Period 2023 to 2030 CAGR4.7%
Growth Drivers
  • Increase in prevalence of degenerative joint diseases
Challenges & Pitfalls
  • Stringent regulatory guidelines on guided bone regeneration


Opportunities
Surging spending on healthcare facilities and treatment will boost the guided bone regeneration market

Restraints
  • Expensive in treatment cost


The Players Covered in the Study are:
Geistlich Pharma (Switzerland), Keystone Dental (United States), Yantai Zhenghai Bio-tech (China), Bio-tech (India), Genoss (South Korea), MegaGen Impant (South Korea), Sunstar (Switzerland), OraPharma (United States), Biomedical Tissues (France) and Botiss (Germany)

Available Customization:
A list of players that can be included in the study on an immediate basis are Dentsply Sirona (United States), Zimmer Biomet (United States) and Lynch Biologics (United States).


Market Development Activities
In September 2019, Zimmer Biomet and Align Technology, a manufacturer of numerous 3D oral scanning equipment for digital restorative dentistry, struck a global distribution partnership.

In December 2019, Geistlich Biomaterials released Geistlich vallomix, the first approved xenogeneic or allogeneic bone substitute. It neatly co-packages two bone substitutes, such as Vallos, a demineralized cortical allograft, and Geistlich Bio-Oss®, the top xenogeneic bone substitute.

Report Objectives / Segmentation Covered

By Type
  • Ceramic-based
  • Polymer-based
  • Growth factor-based
  • Cell-based
  • Others
By Application
  • Orthopedic Surgery
  • Bone Trauma
  • Dental Surgery
  • Others
By End Use
  • Hospital
  • Dental Clinic
  • Academic & Research Centers

By Membrane
  • Reabsorbable Membranes
  • Non-Reabsorbable Membranes

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in prevalence of degenerative joint diseases
    • 3.3. Market Challenges
      • 3.3.1. Stringent regulatory guidelines on guided bone regeneration
    • 3.4. Market Trends
      • 3.4.1. Development of new treatment technology
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Guided Bone Regeneration, by Type, Application, End Use, Membrane and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Guided Bone Regeneration (Value)
      • 5.2.1. Global Guided Bone Regeneration by: Type (Value)
        • 5.2.1.1. Ceramic-based
        • 5.2.1.2. Polymer-based
        • 5.2.1.3. Growth factor-based
        • 5.2.1.4. Cell-based
        • 5.2.1.5. Others
      • 5.2.2. Global Guided Bone Regeneration by: Application (Value)
        • 5.2.2.1. Orthopedic Surgery
        • 5.2.2.2. Bone Trauma
        • 5.2.2.3. Dental Surgery
        • 5.2.2.4. Others
      • 5.2.3. Global Guided Bone Regeneration by: End Use (Value)
        • 5.2.3.1. Hospital
        • 5.2.3.2. Dental Clinic
        • 5.2.3.3. Academic & Research Centers
      • 5.2.4. Global Guided Bone Regeneration by: Membrane (Value)
        • 5.2.4.1. Reabsorbable Membranes
        • 5.2.4.2. Non-Reabsorbable Membranes
      • 5.2.5. Global Guided Bone Regeneration Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Guided Bone Regeneration: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Geistlich Pharma (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Keystone Dental (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Yantai Zhenghai Bio-tech (China)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bio-tech (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genoss (South Korea)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. MegaGen Impant (South Korea)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sunstar (Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. OraPharma (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Biomedical Tissues (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Botiss (Germany)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Guided Bone Regeneration Sale, by Type, Application, End Use, Membrane and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Guided Bone Regeneration (Value)
      • 7.2.1. Global Guided Bone Regeneration by: Type (Value)
        • 7.2.1.1. Ceramic-based
        • 7.2.1.2. Polymer-based
        • 7.2.1.3. Growth factor-based
        • 7.2.1.4. Cell-based
        • 7.2.1.5. Others
      • 7.2.2. Global Guided Bone Regeneration by: Application (Value)
        • 7.2.2.1. Orthopedic Surgery
        • 7.2.2.2. Bone Trauma
        • 7.2.2.3. Dental Surgery
        • 7.2.2.4. Others
      • 7.2.3. Global Guided Bone Regeneration by: End Use (Value)
        • 7.2.3.1. Hospital
        • 7.2.3.2. Dental Clinic
        • 7.2.3.3. Academic & Research Centers
      • 7.2.4. Global Guided Bone Regeneration by: Membrane (Value)
        • 7.2.4.1. Reabsorbable Membranes
        • 7.2.4.2. Non-Reabsorbable Membranes
      • 7.2.5. Global Guided Bone Regeneration Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Guided Bone Regeneration: by Type(USD Million)
  • Table 2. Guided Bone Regeneration Ceramic-based , by Region USD Million (2018-2023)
  • Table 3. Guided Bone Regeneration Polymer-based , by Region USD Million (2018-2023)
  • Table 4. Guided Bone Regeneration Growth factor-based , by Region USD Million (2018-2023)
  • Table 5. Guided Bone Regeneration Cell-based , by Region USD Million (2018-2023)
  • Table 6. Guided Bone Regeneration Others , by Region USD Million (2018-2023)
  • Table 7. Guided Bone Regeneration: by Application(USD Million)
  • Table 8. Guided Bone Regeneration Orthopedic Surgery , by Region USD Million (2018-2023)
  • Table 9. Guided Bone Regeneration Bone Trauma , by Region USD Million (2018-2023)
  • Table 10. Guided Bone Regeneration Dental Surgery , by Region USD Million (2018-2023)
  • Table 11. Guided Bone Regeneration Others , by Region USD Million (2018-2023)
  • Table 12. Guided Bone Regeneration: by End Use(USD Million)
  • Table 13. Guided Bone Regeneration Hospital , by Region USD Million (2018-2023)
  • Table 14. Guided Bone Regeneration Dental Clinic , by Region USD Million (2018-2023)
  • Table 15. Guided Bone Regeneration Academic & Research Centers , by Region USD Million (2018-2023)
  • Table 16. Guided Bone Regeneration: by Membrane(USD Million)
  • Table 17. Guided Bone Regeneration Reabsorbable Membranes , by Region USD Million (2018-2023)
  • Table 18. Guided Bone Regeneration Non-Reabsorbable Membranes , by Region USD Million (2018-2023)
  • Table 19. South America Guided Bone Regeneration, by Country USD Million (2018-2023)
  • Table 20. South America Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 21. South America Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 22. South America Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 23. South America Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 24. Brazil Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 25. Brazil Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 26. Brazil Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 27. Brazil Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 28. Argentina Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 29. Argentina Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 30. Argentina Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 31. Argentina Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 32. Rest of South America Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 33. Rest of South America Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 35. Rest of South America Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 36. Asia Pacific Guided Bone Regeneration, by Country USD Million (2018-2023)
  • Table 37. Asia Pacific Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 38. Asia Pacific Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 40. Asia Pacific Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 41. China Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 42. China Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 43. China Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 44. China Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 45. Japan Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 46. Japan Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 47. Japan Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 48. Japan Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 49. India Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 50. India Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 51. India Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 52. India Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 53. South Korea Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 54. South Korea Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 55. South Korea Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 56. South Korea Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 57. Taiwan Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 58. Taiwan Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 59. Taiwan Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 60. Taiwan Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 61. Australia Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 62. Australia Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 63. Australia Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 64. Australia Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 65. Rest of Asia-Pacific Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 69. Europe Guided Bone Regeneration, by Country USD Million (2018-2023)
  • Table 70. Europe Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 71. Europe Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 72. Europe Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 73. Europe Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 74. Germany Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 75. Germany Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 76. Germany Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 77. Germany Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 78. France Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 79. France Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 80. France Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 81. France Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 82. Italy Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 83. Italy Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 84. Italy Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 85. Italy Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 86. United Kingdom Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 87. United Kingdom Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 88. United Kingdom Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 89. United Kingdom Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 90. Netherlands Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 91. Netherlands Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 92. Netherlands Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 93. Netherlands Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 94. Rest of Europe Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 95. Rest of Europe Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 97. Rest of Europe Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 98. MEA Guided Bone Regeneration, by Country USD Million (2018-2023)
  • Table 99. MEA Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 100. MEA Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 101. MEA Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 102. MEA Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 103. Middle East Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 104. Middle East Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 105. Middle East Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 106. Middle East Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 107. Africa Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 108. Africa Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 109. Africa Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 110. Africa Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 111. North America Guided Bone Regeneration, by Country USD Million (2018-2023)
  • Table 112. North America Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 113. North America Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 114. North America Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 115. North America Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 116. United States Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 117. United States Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 118. United States Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 119. United States Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 120. Canada Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 121. Canada Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 122. Canada Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 123. Canada Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 124. Mexico Guided Bone Regeneration, by Type USD Million (2018-2023)
  • Table 125. Mexico Guided Bone Regeneration, by Application USD Million (2018-2023)
  • Table 126. Mexico Guided Bone Regeneration, by End Use USD Million (2018-2023)
  • Table 127. Mexico Guided Bone Regeneration, by Membrane USD Million (2018-2023)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Guided Bone Regeneration: by Type(USD Million)
  • Table 139. Guided Bone Regeneration Ceramic-based , by Region USD Million (2025-2030)
  • Table 140. Guided Bone Regeneration Polymer-based , by Region USD Million (2025-2030)
  • Table 141. Guided Bone Regeneration Growth factor-based , by Region USD Million (2025-2030)
  • Table 142. Guided Bone Regeneration Cell-based , by Region USD Million (2025-2030)
  • Table 143. Guided Bone Regeneration Others , by Region USD Million (2025-2030)
  • Table 144. Guided Bone Regeneration: by Application(USD Million)
  • Table 145. Guided Bone Regeneration Orthopedic Surgery , by Region USD Million (2025-2030)
  • Table 146. Guided Bone Regeneration Bone Trauma , by Region USD Million (2025-2030)
  • Table 147. Guided Bone Regeneration Dental Surgery , by Region USD Million (2025-2030)
  • Table 148. Guided Bone Regeneration Others , by Region USD Million (2025-2030)
  • Table 149. Guided Bone Regeneration: by End Use(USD Million)
  • Table 150. Guided Bone Regeneration Hospital , by Region USD Million (2025-2030)
  • Table 151. Guided Bone Regeneration Dental Clinic , by Region USD Million (2025-2030)
  • Table 152. Guided Bone Regeneration Academic & Research Centers , by Region USD Million (2025-2030)
  • Table 153. Guided Bone Regeneration: by Membrane(USD Million)
  • Table 154. Guided Bone Regeneration Reabsorbable Membranes , by Region USD Million (2025-2030)
  • Table 155. Guided Bone Regeneration Non-Reabsorbable Membranes , by Region USD Million (2025-2030)
  • Table 156. South America Guided Bone Regeneration, by Country USD Million (2025-2030)
  • Table 157. South America Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 158. South America Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 159. South America Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 160. South America Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 161. Brazil Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 162. Brazil Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 163. Brazil Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 164. Brazil Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 165. Argentina Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 166. Argentina Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 167. Argentina Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 168. Argentina Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 169. Rest of South America Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 170. Rest of South America Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 171. Rest of South America Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 172. Rest of South America Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 173. Asia Pacific Guided Bone Regeneration, by Country USD Million (2025-2030)
  • Table 174. Asia Pacific Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 175. Asia Pacific Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 176. Asia Pacific Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 177. Asia Pacific Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 178. China Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 179. China Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 180. China Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 181. China Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 182. Japan Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 183. Japan Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 184. Japan Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 185. Japan Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 186. India Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 187. India Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 188. India Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 189. India Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 190. South Korea Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 191. South Korea Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 192. South Korea Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 193. South Korea Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 194. Taiwan Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 195. Taiwan Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 196. Taiwan Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 197. Taiwan Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 198. Australia Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 199. Australia Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 200. Australia Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 201. Australia Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 202. Rest of Asia-Pacific Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 203. Rest of Asia-Pacific Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 206. Europe Guided Bone Regeneration, by Country USD Million (2025-2030)
  • Table 207. Europe Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 208. Europe Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 209. Europe Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 210. Europe Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 211. Germany Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 212. Germany Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 213. Germany Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 214. Germany Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 215. France Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 216. France Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 217. France Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 218. France Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 219. Italy Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 220. Italy Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 221. Italy Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 222. Italy Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 223. United Kingdom Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 224. United Kingdom Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 225. United Kingdom Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 226. United Kingdom Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 227. Netherlands Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 228. Netherlands Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 229. Netherlands Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 230. Netherlands Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 231. Rest of Europe Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 232. Rest of Europe Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 233. Rest of Europe Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 234. Rest of Europe Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 235. MEA Guided Bone Regeneration, by Country USD Million (2025-2030)
  • Table 236. MEA Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 237. MEA Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 238. MEA Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 239. MEA Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 240. Middle East Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 241. Middle East Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 242. Middle East Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 243. Middle East Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 244. Africa Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 245. Africa Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 246. Africa Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 247. Africa Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 248. North America Guided Bone Regeneration, by Country USD Million (2025-2030)
  • Table 249. North America Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 250. North America Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 251. North America Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 252. North America Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 253. United States Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 254. United States Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 255. United States Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 256. United States Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 257. Canada Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 258. Canada Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 259. Canada Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 260. Canada Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 261. Mexico Guided Bone Regeneration, by Type USD Million (2025-2030)
  • Table 262. Mexico Guided Bone Regeneration, by Application USD Million (2025-2030)
  • Table 263. Mexico Guided Bone Regeneration, by End Use USD Million (2025-2030)
  • Table 264. Mexico Guided Bone Regeneration, by Membrane USD Million (2025-2030)
  • Table 265. Research Programs/Design for This Report
  • Table 266. Key Data Information from Secondary Sources
  • Table 267. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Guided Bone Regeneration: by Type USD Million (2018-2023)
  • Figure 5. Global Guided Bone Regeneration: by Application USD Million (2018-2023)
  • Figure 6. Global Guided Bone Regeneration: by End Use USD Million (2018-2023)
  • Figure 7. Global Guided Bone Regeneration: by Membrane USD Million (2018-2023)
  • Figure 8. South America Guided Bone Regeneration Share (%), by Country
  • Figure 9. Asia Pacific Guided Bone Regeneration Share (%), by Country
  • Figure 10. Europe Guided Bone Regeneration Share (%), by Country
  • Figure 11. MEA Guided Bone Regeneration Share (%), by Country
  • Figure 12. North America Guided Bone Regeneration Share (%), by Country
  • Figure 13. Global Guided Bone Regeneration share by Players 2023 (%)
  • Figure 14. Global Guided Bone Regeneration share by Players (Top 3) 2023(%)
  • Figure 15. Global Guided Bone Regeneration share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Geistlich Pharma (Switzerland) Revenue, Net Income and Gross profit
  • Figure 18. Geistlich Pharma (Switzerland) Revenue: by Geography 2023
  • Figure 19. Keystone Dental (United States) Revenue, Net Income and Gross profit
  • Figure 20. Keystone Dental (United States) Revenue: by Geography 2023
  • Figure 21. Yantai Zhenghai Bio-tech (China) Revenue, Net Income and Gross profit
  • Figure 22. Yantai Zhenghai Bio-tech (China) Revenue: by Geography 2023
  • Figure 23. Bio-tech (India) Revenue, Net Income and Gross profit
  • Figure 24. Bio-tech (India) Revenue: by Geography 2023
  • Figure 25. Genoss (South Korea) Revenue, Net Income and Gross profit
  • Figure 26. Genoss (South Korea) Revenue: by Geography 2023
  • Figure 27. MegaGen Impant (South Korea) Revenue, Net Income and Gross profit
  • Figure 28. MegaGen Impant (South Korea) Revenue: by Geography 2023
  • Figure 29. Sunstar (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Sunstar (Switzerland) Revenue: by Geography 2023
  • Figure 31. OraPharma (United States) Revenue, Net Income and Gross profit
  • Figure 32. OraPharma (United States) Revenue: by Geography 2023
  • Figure 33. Biomedical Tissues (France) Revenue, Net Income and Gross profit
  • Figure 34. Biomedical Tissues (France) Revenue: by Geography 2023
  • Figure 35. Botiss (Germany) Revenue, Net Income and Gross profit
  • Figure 36. Botiss (Germany) Revenue: by Geography 2023
  • Figure 37. Global Guided Bone Regeneration: by Type USD Million (2025-2030)
  • Figure 38. Global Guided Bone Regeneration: by Application USD Million (2025-2030)
  • Figure 39. Global Guided Bone Regeneration: by End Use USD Million (2025-2030)
  • Figure 40. Global Guided Bone Regeneration: by Membrane USD Million (2025-2030)
  • Figure 41. South America Guided Bone Regeneration Share (%), by Country
  • Figure 42. Asia Pacific Guided Bone Regeneration Share (%), by Country
  • Figure 43. Europe Guided Bone Regeneration Share (%), by Country
  • Figure 44. MEA Guided Bone Regeneration Share (%), by Country
  • Figure 45. North America Guided Bone Regeneration Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Geistlich Pharma (Switzerland)
  • Keystone Dental (United States)
  • Yantai Zhenghai Bio-tech (China)
  • Bio-tech (India)
  • Genoss (South Korea)
  • MegaGen Impant (South Korea)
  • Sunstar (Switzerland)
  • OraPharma (United States)
  • Biomedical Tissues (France)
  • Botiss (Germany)
Additional players considered in the study are as follows:
Dentsply Sirona (United States) , Zimmer Biomet (United States) , Lynch Biologics (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 165 Pages 74 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Guided Bone Regeneration Market Quantitative research analysis
Global Guided Bone Regeneration Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Guided Bone Regeneration market are Geistlich Pharma (Switzerland), Keystone Dental (United States), Yantai Zhenghai Bio-tech (China), Bio-tech (India), Genoss (South Korea), MegaGen Impant (South Korea), Sunstar (Switzerland), OraPharma (United States), Biomedical Tissues (France) and Botiss (Germany), to name a few.
"Development of new treatment technology" is seen as one of major influencing trends for Guided Bone Regeneration Market during projected period 2023-2030.
is dominating the Guided Bone Regeneration Market.
The Guided Bone Regeneration market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete of companies available in our research coverage.

Know More About Global Guided Bone Regeneration Market Report?

Have a Query? Click Here

Other Related Reports

Electronic Prescription Service Comprehensive Study by Type (Integrated Solutions, Standalone Solutions), Deployment Mode (Cloud-Based, On-Premise), End- User (Hospitals, Office-based Physicians, Pha...
$ 3450
Pets Telehealth - Comprehensive Study by Application (Household, Veterinary Clinics), Platform (IOS, Android), Pricing (Monthly Subscription, Annual Subscription), Features (Virtual consultations, Te...
$ 3450
Endophthalmitis Treatment Comprehensive Study by Type (Exogenous {Acute Postoperative, Chronic Postoperative, Traumatic, Filtering Bleb-Associated, After Intravitreal Injections,Corneal ulcer}, Endog...
$ 3650
Medical Second Opinion Services- Comprehensive Study by Application (Patients, Families), Service providers (Hospitals, Medical second opinion providing companies, Health insurance companies), Diseas...
$ 3650
Surgery Management Solutions Comprehensive Study by Type (Services, Software), Application (Anesthesia Information Management Systems, Data Management and Communication Solutions, Operating Room Supp...
$ 3800
Mitral Regurgitation Comprehensive Study by Type (Chronic, Acute), Treatment (Mitral Valve Repair, Medical Therapy, Mitral Valve Replacement, Anticoagulants, Angiotensin-Converting Enzyme (ACE) Inhib...
$ 3800